Skip to main content

Advertisement

SpringerLink
Log in

Will rising prices and budget constraints prevent patients from accessing novel gene therapies?

  • Comment
  • Published:
Gene Therapy Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Gene Therapy Clinical Trials Worldwide. Provided by the Journal of Gene Medicine. http://www.abedia.com/wiley/ (accessed on February 2017).

  2. Corey D. Nature Neuroscience doi:10.1038/nn.4508. Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy. Published online 13 February 2017.

  3. US Food and Drug Administration. FDA approves first drug for spinal muscular atrophy (2016). http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm534611.htm.

  4. Robillard JM, Roskams-Edris D, Kuzeljevic B, Illes J . Prevailing public perceptions of the ethics of gene therapy. Hum Gene Ther 2014; 25: 740–6.

    Article  CAS  Google Scholar 

  5. Blendon RJ, Gorski MT, Benson JM . The Public and the Gene-Editing Revolution. N Engl J Med 2016; 374: 1406–1411.

    Article  Google Scholar 

  6. Spink J, Geddes D . Gene therapy progress and prospects: bringing gene therapy into medical practice. Gene Therapy 2004; 11: 1611–1616.

    Article  CAS  Google Scholar 

  7. Gammie T, Lu CY, Babar Z. Access to orphan drugs: a comprehensive review of legislations, regulations and policies in 365 countries. http://nrs.harvard.edu/urn-3:HUL.InstRepos:23473978.

  8. Orphan Drug Report 2014, Evaluate Pharma. http://info.evaluategroup.com/rs/evaluatepharmaltd/images/2014OD.pdf.

  9. Orphanet Report Series. Lists of medicinal products for rare diseases in Europe. October 2016. http://www.orpha.net/orphacom/cahiers/docs/GB/list_of_orphan_drugs_in_europe.pdf.

  10. $1-million price tag set for Glybera gene therapy. http://blogs.nature.com/tradesecrets/2015/03/03/1-million-price-tag-set-for-glybera-gene-therapy.

Download references

Author information

Authors and Affiliations

  1. Genetic Alliance UK, London, UK

    A Kent & J Spink

Authors
  1. A Kent
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J Spink
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Kent.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kent, A., Spink, J. Will rising prices and budget constraints prevent patients from accessing novel gene therapies?. Gene Ther 24, 542–543 (2017). https://doi.org/10.1038/gt.2017.66

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/gt.2017.66

  • Springer Nature Limited

Search

Navigation